



This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

## Patient Group Direction (PGD)

For the administration or supply of

### Silver Sulfadiazine Cream 1%

By registered health care professionals for

### Prophylaxis and treatment of infection in burn wounds

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

## PGD NUMBER 113

### 1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

## 2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#)

## 3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

## 4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

## 5. PGD adoption by the provider

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job title and organisation	Signature	Date	Applicable or not applicable to area

## 6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	Requirements of registered Healthcare professionals working under the PGD
<b>Qualifications and professional registration</b>	<ul style="list-style-type: none"> <li>Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy</li> <li>Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises</li> </ul>
<b>Initial training</b>	<ul style="list-style-type: none"> <li>Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria</li> <li>Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD</li> <li>Local training in the use of PGD's</li> </ul>
<b>Competency assessment</b>	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGD's
<b>Ongoing training and competency</b>	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

## 7. Clinical Conditions

<b>Clinical condition or situation to which this PGD applies</b>	Prophylaxis and treatment of infection in burn wounds
<b>Inclusion criteria</b>	<ul style="list-style-type: none"> <li>• Adults and Children</li> <li>• Burns</li> </ul>
<b>Exclusion criteria</b>	<ul style="list-style-type: none"> <li>• Neonates</li> <li>• Hypersensitivity to drug or any ingredient</li> <li>• Pregnancy</li> <li>• Breastfeeding</li> <li>• Hepatic or renal impairment</li> <li>• Patients with G6PD deficiency</li> <li>• Wounds with greater than 9% of body area</li> <li>• Concomitant use with enzymatic debriding agents</li> <li>• Patients receiving hypoglycaemic agents and phenytoin - systemic absorption of silver sulphadiazine can potentiate their effects</li> </ul>
<b>Cautions (including any relevant action to be taken)</b>	<ul style="list-style-type: none"> <li>• If large areas of skin are treated, plasma - sulfadiazine concentrates may approach therapeutic levels with side effects and interactions as for sulphonamides</li> <li>• Allergic reactions including burning, itching and rashes</li> <li>• Leucopenia</li> </ul>
<b>Arrangements for referral for medical advice</b>	Patient should be referred to a more experienced clinical practitioner for further assessment
<b>Action to be taken if patient excluded</b>	Patient should be referred to a more experienced clinical practitioner for further assessment
<b>Action to be taken if patient declines treatment</b>	<ul style="list-style-type: none"> <li>• A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment</li> <li>• This information must be documented in the patients' health records</li> <li>• Any patient who declines care must have demonstrated capacity to do so</li> <li>• Where appropriate care should be escalated</li> </ul>

## 8. Details of the medicine

<b>Name, form and strength of medicine</b>	Silver Sulfadiazine Cream 1%
<b>Legal category</b>	Prescription Only Medicine (POM)
<b>Indicate any <u>off-label use</u> (if relevant)</b>	None
<b>Route/method of administration</b>	Topical
<b>Dose and frequency</b>	Apply to cover affected area

<b>Quantity to be administered and/or supplied</b>	As required for size of effected area
<b>Maximum or minimum treatment period</b>	Maximum for one week
<b>Storage</b>	Room temperature
<b>Adverse effects</b>	<ul style="list-style-type: none"> <li>• Allergic reactions</li> <li>• Argyria</li> <li>• Burning</li> <li>• Itching</li> <li>• Leucopenia</li> <li>• Rashes</li> <li>• May inactivate enzymatic debriding agents – concomitant use may be inappropriate.</li> </ul>
<b>Records to be kept</b>	The administration of any medication given under a PGD must be recorded within the patient’s medical records

## 9. Patient information

<b>Verbal/Written information to be given to patient or carer</b>	<ul style="list-style-type: none"> <li>• Keep affected area covered</li> <li>• Verbal information must be given to patients and or carers for all medication being administered under a PGD</li> <li>• Where medication is being supplied under a PGD, written patient information leaflet must also be supplied</li> <li>• A patient information leaflet is available on request</li> </ul>
<b>Follow-up advice to be given to patient or carer</b>	If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

## 10. Appendix A

References
1. British National Formulary (BNF) available online: <a href="https://bnf.nice.org.uk">https://bnf.nice.org.uk</a>
2. Nursing and Midwifery (2018) “The code” available online: <a href="https://www.nmc.org.uk">https://www.nmc.org.uk</a>
3. Current Health Care Professions Council standards of practice
4. General Pharmaceutical Council standards
5. The General Optical Council
6. Electronic medicines compendium available online: <a href="https://www.medicines.org.uk">https://www.medicines.org.uk</a>

## 11. Appendix B

Health professionals agreed to practice
<ul style="list-style-type: none"> <li>• Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor</li> <li>• A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves</li> </ul>